45,217 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Capital International Ltd. CA

Capital International Ltd. CA purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 45,217 shares of the life sciences company's stock, valued at approximately $6,042,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Capital Group Investment Management PTE. LTD. bought a new stake in Illumina during the fourth quarter valued at about $1,307,000. Capital International Sarl purchased a new position in Illumina during the fourth quarter valued at approximately $9,174,000. CANADA LIFE ASSURANCE Co increased its stake in Illumina by 5.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 279,836 shares of the life sciences company's stock worth $37,382,000 after buying an additional 13,563 shares in the last quarter. Farringdon Capital Ltd. bought a new stake in Illumina during the fourth quarter valued at about $206,000. Finally, Zacks Investment Management raised its holdings in Illumina by 3.5% during the fourth quarter. Zacks Investment Management now owns 23,210 shares of the life sciences company's stock valued at $3,102,000 after acquiring an additional 786 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of several research analyst reports. Royal Bank of Canada cut their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. Robert W. Baird cut their price objective on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Canaccord Genuity Group lowered their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a report on Tuesday, March 11th. Piper Sandler lifted their price target on shares of Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Finally, Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Stock Up 2.6 %

ILMN stock traded up $1.95 during trading on Wednesday, hitting $76.30. 630,270 shares of the company's stock traded hands, compared to its average volume of 2,268,646. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The business has a fifty day simple moving average of $83.43 and a two-hundred day simple moving average of $119.36. The firm has a market capitalization of $12.08 billion, a P/E ratio of -9.93, a PEG ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.